The company’s public offering comes after years of growth and demonstrates the changing dynamics of an industry in which smaller R&D entities are becoming increasingly significant players
The enlarged board’s decision that plants produced by biological processes are unpatentable has shocked the IP profession and came after office head António Campinos asked it to look again at previous ruling
Royalty Pharma decision answers important questions about Article 3(a) of the EU’s patent extension rights regulation, but creates new uncertainties Read more
It is a key part of our growth strategy and we actively seek to ensure IP strategies are in place to protect our investment, says senior DuPont counsel Read more
Government responses to the pandemic could include increased focus on obligatory sharing of patented inventions, but regulatory data exclusivities might serve as a barrier in both Europe and the United States. Read more
Design protection has taken on an increasingly important role in recent years, since appearance and exterior shape now play a fundamental role in the success of a product. Designs are now relevant to a wide range of products involving industry,… Read more
A new financing and advisory mechanism to help innovative European SMEs secure high-quality patents and build effective portfolios will be rolled out across Europe in 2019, it was revealed today. The creation of Patent Factory Europe (PFE) was…
The announcement today by the European Commission that Ireland must claw back €13 billion in tax revenues from Apple looks set to escalate the back and forth on the tax practices of major multinationals who use their economic leverage to benefit…
A growing number of patent owners in the European Union probably have the potential to monetise their patents – but do they know the best way to go about this?
All the plenary and breakout sessions have now come to an end at IPBC Global 2016. It’s been one hell of an event. IAM’s editorial team on the ground in Barcelona – editor Joff Wild (JW); North America editor Richard Lloyd (RL); Asia editor Jacob…
With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem Read more
With so many issues emerging across the entire supply chain, the sector’s IP leaders will be sharing their thoughts and insights at events in Detroit and Munich next month Read more
In an exclusive opinion piece for IAM, Jim Beveridge of the Innovators' Network argues that originators need to embrace transparency and avoid royalty stacking to allow IoT innovation to thrive Read more
Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more
After 18 months as head of the European Patent Office, António Campinos shares his vision for the agency's future and talks quality, AI, the UPC, competition between the IP5, getting the examiner corps onside and plenty more on top Read more
Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more
Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more
After 18 months as head of the European Patent Office, António Campinos shares his vision for the agency's future and talks quality, AI, the UPC, competition between the IP5, getting the examiner corps onside and plenty more on top Read more
Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more
Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more
Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more
The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more
Judgments from Europe’s top court rejecting a presumption of confidentiality for clinical study reports submitted for marketing authorisation have significant implications Read more
The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
After months of Truvada controversy, Department of Justice files multi-billion dollar case against Gilead, claiming the company has declined to take a licence to its HIV PrEP rights since in 2016 Read more
With European Parliament elections next week, and a new Commission in the Autumn, it is vital that policymakers are allowed to focus on what is really important: finding ways to build a true European digital innovation ecosystem Read more
In an exclusive opinion piece for IAM, Jim Beveridge of the Innovators' Network argues that originators need to embrace transparency and avoid royalty stacking to allow IoT innovation to thrive Read more
Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more
After 18 months as head of the European Patent Office, António Campinos shares his vision for the agency's future and talks quality, AI, the UPC, competition between the IP5, getting the examiner corps onside and plenty more on top Read more
Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more
Following the EPO’s revocation of the Broad Institute’s key patent, here are the other CRISPR-related appeals and oppositions to watch out for this year Read more
Leading IP professionals give their view on what the British government’s decision not to participate in the system means for pharma and biotech patent litigation in Europe Read more
The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more
The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more
Secret government documents detailing pharma patent discussions between UK and US officials have stirred up a controversy in the run up to the British general election later this month Read more
The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more
Judgments from Europe’s top court rejecting a presumption of confidentiality for clinical study reports submitted for marketing authorisation have significant implications Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more
Judgments from Europe’s top court rejecting a presumption of confidentiality for clinical study reports submitted for marketing authorisation have significant implications Read more
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms Read more
We use cookies on www.iam-media.com. By using this site, you agree that we may store and access cookies on your device. For further information please read our cookie policy and our terms and conditions.
